Agilus Diagnostics publishes data study ahead of World Diabetes Day 2023
India has emerged as the diabetes capital of the world with incidence steadily on the rise over the last three decades. The prevalence of diabetes in India stood at 8.9% in 2019 with more than 77 million people with diabetes….
The American Diabetes Association and Genentech Launch a Call to Action for Eye Exams to Prevent Diabetes-Related Vision Loss
The American Diabetes Association® (ADA), a sponsor of the 2023 Magic City Classic (MCC), and Genentech, anchor partner of the ADA’s Health Equity Now® program, launched the Eye Pledge to Fight Diabetes. This program encourages people with diabetes and their loved ones to…
MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil
MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and the Fast…
Diabetes Capital of the World: From reactive to preventive – The need for a shift in the healthcare dynamics of India
Diabetes, which is commonly known as ‘the sugar disease is a condition that impacts the way our body produces or utilizes insulin hormone. The insulin hormone works like a fuel to the body as it converts food into energy. Any…
MediBuddy records an increase of 86% in queries related to diabetes post-Diwali
MediBuddy, India’s largest digital healthcare platform observed a surge of over 86% in diabetes consultations. The number of consultations on the platform has increased since Diwali, with data indicating that more males than females suffer from diabetes across the country….
Bayer Launches Kerendia™ (finerenone), an Innovative Medicine to Slow Down Progression of Chronic Kidney Disease in Patients with Diabetes
Bayer today announced the launch of Finerenone under the brand name KerendiaTM in India. Finerenone is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease associated with type 2 diabetes. The recent Indian Chronic Kidney…
